HERCULES, Calif., July 07, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of its CFX Automation System II, a robotic plate handler that enables high-throughput, walk-away real-time PCR automation for ...
HERCULES, Calif., February 13, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of an RT-PCR kit that allows researchers to simultaneously screen samples for Zika (ZIKV), dengue (DENV1, DENV2, DENV3, DENV4 ...
Bio-Rad Laboratories has received FDA clearance for two digital PCR products designed to monitor patients’ molecular responses to tyrosine kinase inhibitor treatments in chronic myeloid leukemia. The ...
Bio-Rad’s CFX Opus Deepwell Real-Time PCR Detection System is designed to support researchers in developing nucleic acid detection assays. Bio-Rad Laboratories’s new CFX Opus Deepwell Real-Time ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback